Journal article
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
Abstract
A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive phenotype characterised by decline in lung function, worsening quality of life and early mortality. Other than idiopathic pulmonary fibrosis (IPF), there are no approved drugs for fibrosing ILDs and a poor evidence base to support current treatments. Fibrosing ILDs with a progressive phenotype show commonalities in clinical behaviour and in the …
Authors
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Journal
European Respiratory Journal, Vol. 54, No. 3,
Publisher
European Respiratory Society (ERS)
Publication Date
September 2019
DOI
10.1183/13993003.00161-2019
ISSN
0903-1936